Revenue: Down 27% to $12.2 million in the six months to September 30.
Net loss: $14.5m, improved from a $15.3m loss last year.
Main takeaway: The company is not commenting on whether it needs to raise more capital while it continues to wait for a decision on whether its Cxbladder product will be funded by the US Medicare scheme.
Pacific Edge is not commenting on whether it will need to raise capital soon, instead focusing on potential 2025 catalysts against the ongoing headwind of whether its Cxbladder product will be funded by the US Medicare scheme.
The listed cancer diagnostics company today reported a net loss after tax
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
Revenue: Down 27% to $12.2 million in the six months to September 30.
Net loss: $14.5m, improved from a $15.3m loss last year.
Main takeaway: The company is not commenting on whether it needs to raise more capital while it continues to wait for a decision on whether its Cxbladder product will be funded by the US Medicare scheme.
